Medicines labeled for the same conditions
Alternatives to alirocumab
3 other medicines are given the same way (subcutaneous) and in the same FDA class as alirocumab or labeled mainly for the same use (angina); 1 is in its class, pcsk9 inhibitors: evolocumab; the others include 2 low molecular weight heparins (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $281.96 per mL (Repatha 140 mg/mL sureclick) (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as alirocumab?
Angina lists all 21 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Alirocumabpcsk9 inhibitor | this medicine | none listed | $258.01 per mL 150 mg/mL pen | No | No current entry |
| Evolocumabpcsk9 inhibitor · same class | Angina, Heart attack and coronary artery disease, High cholesterol | none listed | $281.96 per mL 140 mg/mL sureclick | No | No current entry |
| Enoxaparinlow molecular weight heparin | Angina, Heart attack and coronary artery disease | 14 labelers | $6.45 per mL 100 mg/mL syringe | Yes | No current entry |
| Dalteparinlow molecular weight heparin | Angina, Heart attack and coronary artery disease | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Alirocumab: the full record
- label, generics, price, shortages, recalls